<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01765244</url>
  </required_header>
  <id_info>
    <org_study_id>CAH/Ulc/2010</org_study_id>
    <secondary_id>2010-024290-40</secondary_id>
    <nct_id>NCT01765244</nct_id>
  </id_info>
  <brief_title>Allogeneic Tissue Engineering (Nanostructured Artificial Human Cornea) in Patients With Corneal Trophic Ulcers in Advanced Stages, Refractory to Conventional (Ophthalmic) Treatment</brief_title>
  <official_title>Multicenter Clinical Trial to Evaluate the Safety and Feasibility of an Allogeneic Tissue Engineered Drug (Nanostructured Artificial Human Cornea) in Patients With Corneal Trophic Ulcers Refractory to Conventional Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iniciativa Andaluza en Terapias Avanzadas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, phase I-II, randomised, open-label clinical trial that will evaluate
      the safety and feasibility, as well as clinical efficacy evidence, of a bioengineered
      anterior corneal substitute in adults with severe trophic corneal ulcers. This model of human
      anterior allogeneic cornea will provide an alternative approach in cases where human donor
      keratoplasty is not an option.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I-II, randomised, controlled, open-label clinical trial, currently ongoing in
      eleven Spanish hospitals, to evaluate the safety and feasibility, as well as clinical
      efficacy evidence, of a bioengineered human anterior corneal substitute in adults with severe
      trophic corneal ulcers refractory to conventional treatment, or with sequelae of previous
      ulcers. In the initial phase of the trial (n=5), patients were sequentially recruited, with a
      safety period of 45 days, receiving the bioengineered corneal graft. In the second phase of
      the trial (currently ongoing), subjects are block randomised (2:1) to receive either the
      corneal graft (n=10), or amniotic membrane (n=5), as the control treatment. Adverse events,
      implant status, infection signs and induced neovascularization are evaluated as determinants
      of safety and feasibility of the bioengineered graft (main outcomes). Study endpoints are
      measured along a follow-up period of 24 months, including 27 post-implant assessment visits
      according to a decreasing frequency. Intention to treat, and per protocol, and safety
      analysis will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2014</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Bioengineered anterior human corneal substitute Amniotic membrane corneal graft</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (and serious adverse events) causally related to experimental treatment.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Implant status (integrity, detachment and reabsorption)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Local, regional or systemic infections related with the implant</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Induced corneal neovascularization</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ulcer persistency or relapse and corneal stromal repair</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal transparency</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear function (TBUT and Schirmer)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (EQ-5)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Induced chronic ocular complications</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In vivo confocal microscopy (IVCM) analysis of the grafted bioengineered cornea (and AM)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Severe Trophic Corneal Ulcers Refractory to Conventional Treatment</condition>
  <condition>Sequelae of Previous Trophic Corneal Ulcers</condition>
  <arm_group>
    <arm_group_label>Anterior lamellar nanostructured artificial human cornea</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anterior lamellar nanostructured artificial human cornea with allogenic from dead donor and cultured in its inside and allogeneic corneal epithelium cultured in its surface</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amniotic membrane transplantation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amniotic membrane transplantation as conventional treatment of corneal trophic ulcers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anterior lamellar nanostructured artificial human cornea.</intervention_name>
    <description>Implantation of an anterior lamellar nanostructured artificial human cornea with allogeneic cells from dead donors embedded in a fibrin-agarose scaffold</description>
    <arm_group_label>Anterior lamellar nanostructured artificial human cornea</arm_group_label>
    <other_name>Bioengineered human anterior corneal substitute</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Amniotic membrane transplantation</intervention_name>
    <description>Implantation of an amniotic membrane graft to cover the corneal scarring using the mixed graft/patch technique.</description>
    <arm_group_label>Amniotic membrane transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman aged≥18, with no upper age limit.

          -  Patients that give their informed consent for study participation.

          -  Stage 3 Mackie corneal ulcers that do not respond to conventional medical treatment,
             or patients having undergone previous stage 3 Mackie corneal ulcers,33 currently
             suffering sequelae such as stromal fibrosis or corneal thinning, having no effective
             therapeutic alternative.

          -  Stromal involvement, not reaching the Descemet membrane. Central or peripheral
             localization.

          -  Minimum duration of the disease causing the corneal ulcer: 6 weeks.

          -  No active ocular infection.

          -  Patients with normal laboratory parameters as defined by: Leukocytes≥3000 cells/µL;
             Neutrophils≥1500 cells/µL; Platelets≥100 billion/L; AST/ALT≤1.5 ULN; Creatinine≤1.5
             mg/dL.

        Exclusion Criteria:

          -  Absence of stromal involvement.

          -  Good response to standard medical treatments for corneal disease in less than 3 to 5
             weeks.

          -  Bullous keratopathy or other endothelial decompensations.

          -  Active ocular infection.

          -  Positive serology to HBV, HCV, HIV or any other pathology that may interfere with
             correct patient follow-up.

          -  Pregnant or breast-feeding women or childbearing-age women that do not consent the use
             of contraceptive methods approved in the protocol.

          -  Medical history of active neoplasia within the past 5 years. Participation in other
             clinical trials in 3 months previous to inclusion, or in the previous 5 years for
             trials with advanced therapies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Santiago Medialdea, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital U Virgen de las Nieves</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel Alaminos, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universidad de Granada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juliana Martinez-Atienza, PhD</last_name>
    <phone>0034 955048278</phone>
    <email>juliana.martinez.ext@juntadeandalucia.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital San Juan de Dios</name>
      <address>
        <city>Bormujos</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Ruiz Montero, MD</last_name>
      <email>anruizmontero@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Antonio Ruiz Montero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Puerta del Mar</name>
      <address>
        <city>Cádiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belén Hoyos, MD, PhD</last_name>
      <phone>660409473</phone>
      <email>belenhoyossanabria@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Belén Hoyos, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Jesús Cruz, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leticia Royo, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Iratze Zabalza, Zabalza</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital la Arruzafa</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Villarrubia Cuadrado, MD</last_name>
      <email>alvillarrubia@hospitalarruzafa.com</email>
    </contact>
    <investigator>
      <last_name>Alberto Villarrubia Cuadrado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose María Gallardo Galera, MD</last_name>
      <email>josem.gallardo.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>Jose María Gallardo Galera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital San Cecilio</name>
      <address>
        <city>Granada</city>
        <zip>18012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen González, MD, PhD</last_name>
      <phone>625486990</phone>
      <email>carmengonzalez23283@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Serrano, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Inmaculada Domínguez, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen González, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>José Ignacio Muñoz, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José Luis García, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alberto Villarrubia, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santiago Medialdea, MD, PhD</last_name>
      <phone>619271254</phone>
      <email>santiago.medialdea.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>Santiago Medialdea, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Martínez, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José Lucena, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol</name>
      <address>
        <city>Marbella</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yolanda Fernández Barrientos, MD</last_name>
      <email>yfernandezbarrientos@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yolanda Fernández Barrientos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marina Rodriguez Calvo-Mora</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Rodriguez Calvo-Mora</last_name>
      <email>marina.rodriguez.calvomora.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>Marina Rodriguez Calvo-Mora, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatriz Mataix, MD, PhD</last_name>
      <phone>955008696</phone>
      <email>b1mataix@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Jesús Montero, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Almudena García, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuél Caro, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Virgen de Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Ramón del Trigo, MD, PhD</last_name>
      <phone>630926841</phone>
      <email>deltrigo@telefonica.net</email>
    </contact>
    <investigator>
      <last_name>Juan Ramón del Trigo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana María Muñoz, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Vázquez, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Señora de Valme</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana García Bernal, MD</last_name>
      <email>anagarbe@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ana García Bernal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.juntadeandalucia.es/terapiasavanzadas/</url>
    <description>Andalusian Initiative for Advanced Therapies</description>
  </link>
  <reference>
    <citation>González-Andrades M, Mata R, González-Gallardo MDC, Medialdea S, Arias-Santiago S, Martínez-Atienza J, Ruiz-García A, Pérez-Fajardo L, Lizana-Moreno A, Garzón I, Campos A, Alaminos M, Carmona G, Cuende N. A study protocol for a multicentre randomised clinical trial evaluating the safety and feasibility of a bioengineered human allogeneic nanostructured anterior cornea in patients with advanced corneal trophic ulcers refractory to conventional treatment. BMJ Open. 2017 Sep 24;7(9):e016487. doi: 10.1136/bmjopen-2017-016487.</citation>
    <PMID>28947445</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2013</study_first_submitted>
  <study_first_submitted_qc>January 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2013</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Corneal trophic ulcers, limbal deficiency, cornea blindness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Corneal Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

